Search ARM

Humacyte is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex organ disease. Located in Durham, N.C., Humacyte announced the intent to go public via a SPAC in February 2021. The company was founded in 2004 by Laura Niklason, MD, Ph.D., a world leader in tissue engineering and the Chief Executive Officer of Humacyte, along with Drs. Juliana Blum and Shannon Dahl.

Contact Humacyte
Visit Website